LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 22

Search options

  1. Article ; Online: Diagnostics of Ebola virus.

    Bettini, Aurora / Lapa, Daniele / Garbuglia, Anna Rosa

    Frontiers in public health

    2023  Volume 11, Page(s) 1123024

    Abstract: Ebola is a highly pathogenic virus, which in humans reaches a mortality rate above 50%. Due to a lack of laboratories in territories where Ebola viruses are endemic and the limited number of surveillance programmes, tests for the confirmation of ... ...

    Abstract Ebola is a highly pathogenic virus, which in humans reaches a mortality rate above 50%. Due to a lack of laboratories in territories where Ebola viruses are endemic and the limited number of surveillance programmes, tests for the confirmation of suspected cases of Ebola are often performed in Reference Laboratories. While this provides guarantees regarding the accuracy of results, the shipment of samples to a centralized facility where the diagnostic test can be performed and the time required to achieve the results takes several days, which increases costs and entails delays in the isolation of positive subjects and therapeutic intervention with negative consequences both for patients and the community. Molecular tests have been the most frequently used tool in Ebola diagnosis in recent outbreaks. One of the most commonly used molecular tests is the Real-Star Altona, which targets a conserved area of the L gene. This assay showed different sensitivities depending on the Ebola virus: 471 copies/mL (EBOV) and 2871 copies/ml (SUDAN virus). The Cepheid system also showed good sensitivity (232 copies/mL). The LAMP platform is very promising because, being an isothermal reaction, it does not require high-precision instrumentation and can be considered a Point of Care (PoC) tool. Its analytical sensitivity is 1 copy/reaction. However, since data from real life studies are not yet available, it is premature to give any indications on its feasibility. Moreover, in November 2014, the WHO recommended the development of rapid diagnostic tests (RDT) according to ASSURED criteria. Several RDT assays have since been produced, most of which are rapid tests based on the search for antibody anti-Ebola viral proteins with immunochromatographic methods. Several viral antigens are used for this purpose: VP40, NP and GP. These assays show different sensitivities according to the protein used: VP40 57.4-93.1%, GP 53-88.9% and 85% for NP compared to reference molecular assays. From these results, it can be deduced that no RDT reaches the 99% sensitivity recommended by the WHO and therefore any RDT negative results in suspected cases should be confirmed with a molecular test.
    MeSH term(s) Humans ; Ebolavirus/genetics ; Sensitivity and Specificity ; Hemorrhagic Fever, Ebola/epidemiology ; Point-of-Care Systems ; Disease Outbreaks
    Language English
    Publishing date 2023-02-23
    Publishing country Switzerland
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2711781-9
    ISSN 2296-2565 ; 2296-2565
    ISSN (online) 2296-2565
    ISSN 2296-2565
    DOI 10.3389/fpubh.2023.1123024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Asymptomatic Mpox Virus Infection in Subjects Presenting for MVA-BN Vaccine.

    Matusali, Giulia / Mazzotta, Valentina / Piselli, Pierluca / Bettini, Aurora / Colavita, Francesca / Coen, Sabrina / Vaia, Francesco / Girardi, Enrico / Antinori, Andrea / Maggi, Fabrizio

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2023  Volume 77, Issue 10, Page(s) 1483–1484

    MeSH term(s) Humans ; Monkeypox virus/immunology ; Mpox (monkeypox) ; Smallpox Vaccine/immunology ; Vaccinia virus/immunology ; Antibodies, Neutralizing
    Chemical Substances smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic (TU8J357395) ; Smallpox Vaccine ; Antibodies, Neutralizing
    Language English
    Publishing date 2023-07-03
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciad414
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Effect of chemical and physical agents on monkeypox virus infectivity and downstream research applications.

    Mariotti, Davide / Bettini, Aurora / Meschi, Silvia / Notari, Stefania / Francalancia, Massimo / Tartaglia, Eleonora / Lapa, Daniele / Specchiarello, Eliana / Girardi, Enrico / Matusali, Giulia / Maggi, Fabrizio

    Virology

    2024  Volume 592, Page(s) 109993

    Abstract: The 2022 global spread of Monkeypox Virus (MPXV) underlined the need to investigate safe-handling procedures of clinical and research samples. Here we evaluated the efficiency in reducing MPXV infectious titer of Triton X-100 (0.1 and 0.2%), UV-C ... ...

    Abstract The 2022 global spread of Monkeypox Virus (MPXV) underlined the need to investigate safe-handling procedures of clinical and research samples. Here we evaluated the efficiency in reducing MPXV infectious titer of Triton X-100 (0.1 and 0.2%), UV-C irradiation (15 or 30 min), and heat (56 °C 30 min or 70 °C 5 min). The treatment of MPXV at 70 °C resulted in the strongest decrease of MPXV infectious titer (5.4 Log TCID50/mL), 56 °C and UV-C had a lighter impact (3.9 and 4.3Log), Triton X-100 was less efficient (1.8-2.5Log). Notably, SARS-CoV-2 was much more susceptible to Triton X-100 (4.0 Log decrease). UV-C had the highest impact on MPXV DNA detection by PCR (2.2-4.3 Ct value increase); protein detection by ELISA was dramatically impaired by heating. Overall, UV-C and heating were more effective in lowering MPXV infectious titer but their impact on nucleic acids or protein detection assays must be considered.
    MeSH term(s) Humans ; Monkeypox virus/genetics ; Mpox (monkeypox) ; Octoxynol ; SARS-CoV-2
    Chemical Substances Octoxynol (9002-93-1)
    Language English
    Publishing date 2024-01-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 200425-2
    ISSN 1096-0341 ; 0042-6822
    ISSN (online) 1096-0341
    ISSN 0042-6822
    DOI 10.1016/j.virol.2024.109993
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV.

    Matusali, Giulia / Mazzotta, Valentina / Meschi, Silvia / Colavita, Francesca / Gagliardini, Roberta / Bettini, Aurora / Gruber, Cesare Ernesto Maria / Vergori, Alessandra / Gallì, Paola / Focosi, Daniele / Girardi, Enrico / Antinori, Andrea / Maggi, Fabrizio

    Journal of medical virology

    2024  Volume 96, Issue 5, Page(s) e29631

    MeSH term(s) Humans ; Health Personnel ; HIV Infections/immunology ; HIV Infections/prevention & control ; Antibodies, Neutralizing/blood ; Antibodies, Neutralizing/immunology ; COVID-19 Vaccines/immunology ; COVID-19 Vaccines/administration & dosage ; Adult ; Male ; Female ; COVID-19/prevention & control ; COVID-19/immunology ; Immunization, Secondary ; HIV Antibodies/blood ; HIV Antibodies/immunology ; Middle Aged ; SARS-CoV-2/immunology
    Chemical Substances Antibodies, Neutralizing ; COVID-19 Vaccines ; HIV Antibodies
    Language English
    Publishing date 2024-04-29
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.29631
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Evidence of Maternal Antibodies Elicited by COVID-19 Vaccination in Amniotic Fluid: Report of Two Cases in Italy

    Colavita, Francesca / Oliva, Alessandra / Bettini, Aurora / Antinori, Andrea / Girardi, Enrico / Castilletti, Concetta / Vaia, Francesco / Liuzzi, Giuseppina

    Viruses. 2022 July 21, v. 14, no. 7

    2022  

    Abstract: With SARS-CoV-2 infection, pregnant women may be at a high risk of severe disease and adverse perinatal outcomes. A COVID-19 vaccination campaign represents the key strategy to combat the pandemic; however, public acceptance of maternal immunization has ... ...

    Abstract With SARS-CoV-2 infection, pregnant women may be at a high risk of severe disease and adverse perinatal outcomes. A COVID-19 vaccination campaign represents the key strategy to combat the pandemic; however, public acceptance of maternal immunization has to be improved, which may be achieved by highlighting the promising mechanism of passive immunity as a strategy for protecting newborns against SARS-CoV-2 infection. We tested the anti-SARS-CoV-2 antibody response following COVID-19 full-dose vaccination in the serum and amniotic fluid of two pregnant women who presented between April and June 2021, at the Center for the Treatment and Prevention of Infections in Pregnancy of the National Institute for Infectious Diseases “L. Spallanzani”, for antenatal consultancy. Anti-SARS-CoV-2 IgG was found in residual samples of amniotic fluid collected from both women at the 18th week of gestation (63 and 131 days after the second dose’s administration). Titers in amniotic fluid mirrored the levels detected in serum and were inversely linked to the time from vaccination. Our results suggest that antibodies elicited by COVID-19 vaccination can cross the placenta and reach the fetus; therefore, they may offer passive immunity at birth. It is critical to fully understand the kinetics of the maternal response to vaccination, the efficiency of IgG transfer, and the persistence of antibodies in infants to optimize maternal immunization regimens.
    Keywords COVID-19 infection ; Severe acute respiratory syndrome coronavirus 2 ; amniotic fluid ; antibody formation ; blood serum ; disease severity ; fetus ; pandemic ; placenta ; pregnancy ; risk ; vaccination ; Italy
    Language English
    Dates of publication 2022-0721
    Publishing place Multidisciplinary Digital Publishing Institute
    Document type Article
    ZDB-ID 2516098-9
    ISSN 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v14071592
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  6. Article ; Online: Evidence of Maternal Antibodies Elicited by COVID-19 Vaccination in Amniotic Fluid: Report of Two Cases in Italy.

    Colavita, Francesca / Oliva, Alessandra / Bettini, Aurora / Antinori, Andrea / Girardi, Enrico / Castilletti, Concetta / Vaia, Francesco / Liuzzi, Giuseppina

    Viruses

    2022  Volume 14, Issue 7

    Abstract: With SARS-CoV-2 infection, pregnant women may be at a high risk of severe disease and adverse perinatal outcomes. A COVID-19 vaccination campaign represents the key strategy to combat the pandemic; however, public acceptance of maternal immunization has ... ...

    Abstract With SARS-CoV-2 infection, pregnant women may be at a high risk of severe disease and adverse perinatal outcomes. A COVID-19 vaccination campaign represents the key strategy to combat the pandemic; however, public acceptance of maternal immunization has to be improved, which may be achieved by highlighting the promising mechanism of passive immunity as a strategy for protecting newborns against SARS-CoV-2 infection. We tested the anti-SARS-CoV-2 antibody response following COVID-19 full-dose vaccination in the serum and amniotic fluid of two pregnant women who presented between April and June 2021, at the Center for the Treatment and Prevention of Infections in Pregnancy of the National Institute for Infectious Diseases "L. Spallanzani", for antenatal consultancy. Anti-SARS-CoV-2 IgG was found in residual samples of amniotic fluid collected from both women at the 18th week of gestation (63 and 131 days after the second dose's administration). Titers in amniotic fluid mirrored the levels detected in serum and were inversely linked to the time from vaccination. Our results suggest that antibodies elicited by COVID-19 vaccination can cross the placenta and reach the fetus; therefore, they may offer passive immunity at birth. It is critical to fully understand the kinetics of the maternal response to vaccination, the efficiency of IgG transfer, and the persistence of antibodies in infants to optimize maternal immunization regimens.
    MeSH term(s) Amniotic Fluid ; Antibodies, Viral ; COVID-19/prevention & control ; COVID-19 Vaccines ; Female ; Humans ; Immunoglobulin G ; Infant ; Infant, Newborn ; Pregnancy ; Pregnancy Complications, Infectious/prevention & control ; SARS-CoV-2 ; Vaccination
    Chemical Substances Antibodies, Viral ; COVID-19 Vaccines ; Immunoglobulin G
    Language English
    Publishing date 2022-07-21
    Publishing country Switzerland
    Document type Case Reports ; Research Support, Non-U.S. Gov't
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v14071592
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Profiling the acute phase antibody response against mpox virus in patients infected during the 2022 outbreak.

    Colavita, Francesca / Matusali, Giulia / Mazzotta, Valentina / Bettini, Aurora / Lapa, Daniele / Meschi, Silvia / Francalancia, Massimo / Pinnetti, Carmela / Bordi, Licia / Mizzoni, Klizia / Coen, Sabrina / Girardi, Enrico / Vaia, Francesco / Nicastri, Emanuele / Antinori, Andrea / Maggi, Fabrizio

    Journal of medical virology

    2023  Volume 95, Issue 6, Page(s) e28851

    Abstract: Information on the immune response during the mpox virus (MPXV) infection is still scarce or limited to past studies when cross-reactive immunity from smallpox vaccination was predominant. Here, we describe the short-term kinetics of the antibody ... ...

    Abstract Information on the immune response during the mpox virus (MPXV) infection is still scarce or limited to past studies when cross-reactive immunity from smallpox vaccination was predominant. Here, we describe the short-term kinetics of the antibody response in patients with acute MPXV infection during the 2022 multicountry outbreak. A total of 64 samples from 18 MPXV-positive patients were longitudinally collected from the day of symptom onset (DSO) up to 20 days after and tested for anti-MPXV immunoglobulin G (IgG), IgM, IgA, and neutralizing antibodies (nAb) using the whole-live virus isolated in May 2022. IgG, IgM, and IgA were detected as early as 4 DSO (median time of seroconversion 7.5 DSO for IgG, 8 DSO for IgM and IgA). Anti-MPXV nAb were detectable in samples collected as early as 1 week after symptoms, with stable levels up to 20 DSO. After 2 weeks, IgG and nAb reached high titers. No significant differences were observed regardless of status of smallpox vaccination, human immunodeficiency virus positivity, or disease severity. Significant lower levels of IgM and IgG were observed in the patients treated with antivirals. These results contribute to extending the knowledge of the MPXV infection and the antibody response in a population with no historic smallpox vaccination.
    MeSH term(s) Humans ; Monkeypox virus ; Immunoglobulin G ; Immunoglobulin M ; Smallpox ; Antibody Formation ; Antibodies, Viral ; Antibodies, Neutralizing ; Immunoglobulin A ; Disease Outbreaks
    Chemical Substances Immunoglobulin G ; Immunoglobulin M ; Antibodies, Viral ; Antibodies, Neutralizing ; Immunoglobulin A
    Language English
    Publishing date 2023-06-08
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.28851
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.

    D'Apice, Luciana / Trovato, Maria / Gramigna, Giulia / Colavita, Francesca / Francalancia, Massimo / Matusali, Giulia / Meschi, Silvia / Lapa, Daniele / Bettini, Aurora / Mizzoni, Klizia / Aurisicchio, Luigi / Di Caro, Antonino / Castilletti, Concetta / De Berardinis, Piergiuseppe

    Frontiers in immunology

    2022  Volume 13, Page(s) 981693

    Abstract: Objectives: Emergence of new variants of SARS-CoV-2 might affect vaccine efficacy. Therefore, assessing the capacity of sera to neutralize variants of concern (VOCs) in BSL-2 conditions will help evaluating the immune status of population following ... ...

    Abstract Objectives: Emergence of new variants of SARS-CoV-2 might affect vaccine efficacy. Therefore, assessing the capacity of sera to neutralize variants of concern (VOCs) in BSL-2 conditions will help evaluating the immune status of population following vaccination or infection.
    Methods: Pseudotyped viruses bearing SARS-CoV-2 spike protein from Wuhan-Hu-1/D614G strains (wild type, WT), B.1.617.2 (Delta), or B.1.1.529 (Omicron) VOCs were generated to assess the neutralizing antibodies (nAbs) activity by a pseudovirus-based neutralization assay (PVNA). PVNA performance was assessed in comparison to the micro-neutralization test (MNT) based on live viruses. Sera collected from COVID-19 convalescents and vaccinees receiving mRNA (BNT16b2 or mRNA-1273) or viral vector (AZD1222 or Ad26.COV2.S) vaccines were used to measure nAbs elicited by two-dose BNT16b2, mRNA-1273, AZD1222 or one-dose Ad26.CO2.S, at different times from completed vaccination, ~ 1.5 month and ~ 4-6 months. Sera from pre-pandemic and unvaccinated individuals were analyzed as controls. Neutralizing activity following booster vaccinations against VOCs was also determined.
    Results: PVNA titers correlated with the gold standard MNT assay, validating the reliability of PVNA. Sera analyzed late from the second dose showed a reduced neutralization activity compared to sera collected earlier. Ad26.CO2.S vaccination led to very low or absent nAbs. Neutralization of Delta and Omicron BA.1 VOCs showed significant reduction of nAbs respect to WT strain. Importantly, booster doses enhanced Omicron BA.1 nAbs, with persistent levels at 3 months from boosting.
    Conclusions: PVNA is a reliable tool for assessing anti-SARS-CoV-2 nAbs helping the establishment of a correlate of protection and the management of vaccination strategies.
    MeSH term(s) Ad26COVS1 ; Antibodies, Neutralizing ; COVID-19/prevention & control ; Carbon Dioxide ; ChAdOx1 nCoV-19 ; Humans ; Membrane Glycoproteins/metabolism ; RNA Viruses ; RNA, Messenger ; Reproducibility of Results ; SARS-CoV-2/genetics ; Spike Glycoprotein, Coronavirus ; Viral Envelope Proteins
    Chemical Substances Ad26COVS1 ; Antibodies, Neutralizing ; Membrane Glycoproteins ; RNA, Messenger ; Spike Glycoprotein, Coronavirus ; Viral Envelope Proteins ; spike protein, SARS-CoV-2 ; Carbon Dioxide (142M471B3J) ; ChAdOx1 nCoV-19 (B5S3K2V0G8)
    Language English
    Publishing date 2022-09-26
    Publishing country Switzerland
    Document type Comparative Study ; Journal Article
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2022.981693
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up.

    Matusali, Giulia / Sberna, Giuseppe / Meschi, Silvia / Gramigna, Giulia / Colavita, Francesca / Lapa, Daniele / Francalancia, Massimo / Bettini, Aurora / Capobianchi, Maria R / Puro, Vincenzo / Castilletti, Concetta / Vaia, Francesco / Bordi, Licia

    Viruses

    2022  Volume 14, Issue 2

    Abstract: To investigate the dynamic association among binding and functional antibodies in health-care-workers receiving two doses of BNT162b2 mRNA COVID-19-vaccine, SARS-CoV-2 anti-RBD IgG, anti-Trimeric-S IgG, and neutralizing antibodies (Nabs) were measured in ...

    Abstract To investigate the dynamic association among binding and functional antibodies in health-care-workers receiving two doses of BNT162b2 mRNA COVID-19-vaccine, SARS-CoV-2 anti-RBD IgG, anti-Trimeric-S IgG, and neutralizing antibodies (Nabs) were measured in serum samples collected at 2 weeks, 3 months, and 6 months from full vaccination. Despite the high correlation, results for anti-RBD and anti-Trimeric S IgG were numerically different even after recalculation to BAU/mL following WHO standards indications. Moreover, after a peak response at 2 weeks, anti-RBD IgG levels showed a 4.5 and 13 fold decrease at 3 and 6 months, respectively, while the anti-Trimeric S IgG presented a less pronounced decay of 2.8 and 4.7 fold. Further different dynamics were observed for Nabs titers, resulting comparable at 3 and 6 months from vaccination. We also demonstrated that at NAbs titers ≥40, the area under the receiver operating characteristic curve and the optimal cutoff point decreased with time from vaccination for both anti-RBD and anti-Trimeric S IgG. The mutating relation among the anti-RBD IgG, anti-Trimeric S IgG, and neutralizing antibodies are indicative of antibody maturation upon vaccination. The lack of standardized laboratory procedures is one factor interfering with the definition of a correlate of protection from COVID-19.
    MeSH term(s) Adult ; Antibodies, Neutralizing/blood ; Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/metabolism ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; Antibodies, Viral/metabolism ; BNT162 Vaccine/administration & dosage ; BNT162 Vaccine/immunology ; Binding Sites, Antibody ; COVID-19/immunology ; COVID-19/prevention & control ; Cohort Studies ; Female ; Follow-Up Studies ; Health Personnel/statistics & numerical data ; Humans ; Immunity, Humoral ; Immunoglobulin G/blood ; Immunoglobulin G/immunology ; Immunoglobulin G/metabolism ; Kinetics ; Longitudinal Studies ; Male ; Middle Aged ; SARS-CoV-2/immunology ; SARS-CoV-2/metabolism ; Vaccination
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; Immunoglobulin G ; BNT162 Vaccine (N38TVC63NU)
    Language English
    Publishing date 2022-02-02
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v14020312
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up

    Matusali, Giulia / Sberna, Giuseppe / Meschi, Silvia / Gramigna, Giulia / Colavita, Francesca / Lapa, Daniele / Francalancia, Massimo / Bettini, Aurora / Capobianchi, Maria R. / Puro, Vincenzo / Castilletti, Concetta / Vaia, Francesco / Bordi, Licia

    Viruses. 2022 Feb. 02, v. 14, no. 2

    2022  

    Abstract: To investigate the dynamic association among binding and functional antibodies in health-care-workers receiving two doses of BNT162b2 mRNA COVID-19-vaccine, SARS-CoV-2 anti-RBD IgG, anti-Trimeric-S IgG, and neutralizing antibodies (Nabs) were measured in ...

    Abstract To investigate the dynamic association among binding and functional antibodies in health-care-workers receiving two doses of BNT162b2 mRNA COVID-19-vaccine, SARS-CoV-2 anti-RBD IgG, anti-Trimeric-S IgG, and neutralizing antibodies (Nabs) were measured in serum samples collected at 2 weeks, 3 months, and 6 months from full vaccination. Despite the high correlation, results for anti-RBD and anti-Trimeric S IgG were numerically different even after recalculation to BAU/mL following WHO standards indications. Moreover, after a peak response at 2 weeks, anti-RBD IgG levels showed a 4.5 and 13 fold decrease at 3 and 6 months, respectively, while the anti-Trimeric S IgG presented a less pronounced decay of 2.8 and 4.7 fold. Further different dynamics were observed for Nabs titers, resulting comparable at 3 and 6 months from vaccination. We also demonstrated that at NAbs titers ≥40, the area under the receiver operating characteristic curve and the optimal cutoff point decreased with time from vaccination for both anti-RBD and anti-Trimeric S IgG. The mutating relation among the anti-RBD IgG, anti-Trimeric S IgG, and neutralizing antibodies are indicative of antibody maturation upon vaccination. The lack of standardized laboratory procedures is one factor interfering with the definition of a correlate of protection from COVID-19.
    Keywords COVID-19 infection ; Severe acute respiratory syndrome coronavirus 2 ; blood serum ; vaccination ; vaccines
    Language English
    Dates of publication 2022-0202
    Publishing place Multidisciplinary Digital Publishing Institute
    Document type Article
    ZDB-ID 2516098-9
    ISSN 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v14020312
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

To top